Sangamo Therapeutics, Inc.
SGMO
$0.14
$0.000.22%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 14.23M | 581.00K | 18.31M | 6.44M | 7.55M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.23M | 581.00K | 18.31M | 6.44M | 7.55M |
| Cost of Revenue | 31.44M | 28.14M | 27.08M | 24.81M | 23.48M |
| Gross Profit | -17.21M | -27.56M | -8.78M | -18.37M | -15.92M |
| SG&A Expenses | 7.76M | 7.99M | 9.08M | 10.06M | 9.87M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.20M | 36.13M | 36.16M | 34.87M | 33.34M |
| Operating Income | -24.97M | -35.55M | -17.86M | -28.43M | -25.79M |
| Income Before Tax | -37.97M | -35.09M | -19.96M | -30.48M | -23.82M |
| Income Tax Expenses | -553.00K | -161.00K | 27.00K | 119.00K | -427.00K |
| Earnings from Continuing Operations | -37.42M | -34.93M | -19.99M | -30.60M | -23.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.42M | -34.93M | -19.99M | -30.60M | -23.40M |
| EBIT | -24.97M | -35.55M | -17.86M | -28.43M | -25.79M |
| EBITDA | -24.01M | -34.56M | -16.86M | -27.41M | -24.55M |
| EPS Basic | -0.11 | -0.11 | -0.08 | -0.14 | -0.11 |
| Normalized Basic EPS | -0.05 | -0.07 | -0.05 | -0.08 | -0.07 |
| EPS Diluted | -0.11 | -0.11 | -0.08 | -0.14 | -0.12 |
| Normalized Diluted EPS | -0.05 | -0.07 | -0.05 | -0.08 | -0.07 |
| Average Basic Shares Outstanding | 337.73M | 304.27M | 256.95M | 220.27M | 210.19M |
| Average Diluted Shares Outstanding | 337.73M | 304.27M | 256.95M | 220.27M | 210.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |